Year: 2013
Type: article
Abstract: Dr Stone has raised meritorious points regarding the treatment of intermediate-risk prostate cancer and the potential concerns of supplemental external beam radiotherapy (EBRT) (1). However, within all the arguments he posed to support the routine use of brachytherapy alone for intermediate-risk disease, there are inconsistencies. Indeed, some of his perspectives actually represent cogent reasons to support our viewpoint for adding supplemental EBRT to brachytherapy in this patient population. So for this rebuttal, let's carefully analyze Dr Stone's arguments for the use of brachytherapy alone.
Source: Brachytherapy
Authors: Daniel E. Spratt, Michael J. Zelefsky
Institution: Memorial Sloan Kettering Cancer Center
Language: English
Subfield: Urology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,000
OpenAlex ID: W2130611425